KCNH2 and neoplasm: Based on its half-life (25 hours), scDb-hERG1-β1-TRAIL was administered intravenously every 48 hours for either 7 (model 1) or 21 days (model 2) at the dose of 35 mg/kg, starting when the tumor masses reached a volume of 180 mm3 (model 1) or 30 mm3 (model 2; see the schemes on the bottoms of Fig. 6A and C).